PFIZER INC Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 37 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-08-28: Reporting owner Guegan Cecile; Form 3; Security Stock Appreciation Rights; Transaction Holding.
- 2026-08-28: Reporting owner Guegan Cecile; Form 3; Security Stock Appreciation Rights; Transaction Holding.
- 2026-08-28: Reporting owner Guegan Cecile; Form 3; Security Stock Appreciation Rights; Transaction Holding.
- 2026-08-28: Reporting owner Guegan Cecile; Form 3; Security Stock Appreciation Rights; Transaction Holding.
PFE insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $25.75 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $26.58 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $26.89 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $26.89 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $31.31 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $33.82 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $42.30 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $42.30 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $45.96 exercise price | 2026-08-28 | ||
| 2026-08-28 holding as of filing | Guegan Cecile Officer (Executive Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $45.96 exercise price | 2026-08-28 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $25.75 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $26.58 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $26.89 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $26.89 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $31.31 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $33.82 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $42.30 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $42.30 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $45.96 exercise price | 2026-04-10 | ||
| 2026-04-10 holding as of filing | Hancock Dennis P Officer (Senior Vice President) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $45.96 exercise price | 2026-04-10 | ||
| 2026-03-03 | DAMICO JENNIFER B. Officer (SVP & Controller) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,638 22,638 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | BOURLA ALBERT Director, Officer (Chairman & CEO) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +708,666 708,666 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | BOSHOFF CHRISTOFFEL Officer (President, R&D) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +259,844 259,844 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | Denton David M Officer (Chief Financial Officer & EVP) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +216,537 216,537 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | LANKLER DOUGLAS M Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +194,883 194,883 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | MALIK AAMIR Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +194,883 194,883 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | Baum Andrew Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +303,151 303,151 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | Fonseca Lidia Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,284 82,284 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | McDermott Michael Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +151,576 151,576 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | SAHNI PAYAL Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +108,268 108,268 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-03-03 | de Germay Alexandre Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +194,883 194,883 owned after | $26.58 exercise price | $26.58 | 2026-03-05 |
| 2026-02-25 | SAHNI PAYAL Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −56,888 0 owned after | $33.82 exercise price | $27.09 | 2026-02-27 |
| 2026-02-25 | LANKLER DOUGLAS M Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −122,907 0 owned after | $33.82 exercise price | $27.09 | 2026-02-27 |
| 2026-02-25 | DAMICO JENNIFER B. Officer (SVP & Controller) | 4 | Stock Appreciation Rights Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,558 0 owned after | $33.82 exercise price | $27.09 | 2026-02-27 |
| 2026-02-25 | BOURLA ALBERT Director, Officer (Chairman & CEO) | 4 | Stock Appreciation Rights Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −491,626 0 owned after | $33.82 exercise price | $27.09 | 2026-02-27 |
| 2026-02-25 | Fonseca Lidia Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −56,888 0 owned after | $33.82 exercise price | $27.09 | 2026-02-27 |
| 2026-02-25 | McDermott Michael Officer (Executive Vice President) | 4 | Stock Appreciation Rights Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −37,925 0 owned after | $33.82 exercise price | $27.09 | 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |